Metsera Reports Highly Competitive Results from Ongoing Trial …
WEB3 days ago · NEW YORK, September 24, 2024--Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced positive ...
Metsera Reports Highly Competitive Results from Ongoing
WEB3 days ago · Metsera launching Phase 2b trials in Q4 2024, with data anticipated in first half of 2025 NEW YORK--(BUSINESS WIRE)--Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced positive topline results from the Phase 1 clinical trial of MET-097, an ...
News - Metsera
WEBMetsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape.
Metsera touts long-acting GLP-1 drug; Novartis strikes an AI deal
WEB3 days ago · To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Today, a brief rundown of news from Metsera and Novartis, as well as updates from Sanofi and Wave Life ...
Metsera Announces Positive Phase 1 Results for MET-097, an …
WEB1 day ago · In a Phase 1 clinical trial, Metsera's MET-097 exhibited promising weight loss outcomes, supporting its potential for once-monthly dosing. The 125 participants in the trial received various doses of MET-097. Key Findings: • MET-097 demonstrated significant and sustained weight loss, achieving a 7.5% reduction in body weight. • The weight loss was maintained for at
Readout Newsletter: Metsera, Novo Nordisk, Bluebird Bio updates …
WEB3 days ago · This morning, Metsera, a new obesity biotech, reported that its GLP-1 drug led to substantial and durable weight loss in a Phase 1 study. The highest dose of the drug tested, 1.2 mg, was given ...
New Weight Loss Biotech Metsera Stuns with 7.5% Weight Loss
WEBFive months after launching, Metsera is making waves with Phase I results for a long-acting GLP-1 injectable showing a 7.5% reduction in body weight at day 36. The biotech said …
Metsera Launches to Lead the Next Generation of Medicines for …
WEBApr 18, 2024 · Metsera is a clinical-stage company that launched in 2022 with $290 million in financing. It aims to develop next-generation medicines for weight loss, obesity-related conditions and metabolic...
Arch-backed obesity biotech launches with $290M - Fierce Biotech
WEBMetseraCEO Clive Meanwell, M.D. (Metsera) Meanwell also helped form and is a partner of private equity firm Population Health Partners. The firm, alongside Arch Venture …
Metsera, a well-funded obesity drug startup, sees chance to …
WEBApr 18, 2024 · Metsera, launched in 2024, aims to develop weight loss medicines that can compete with Novo Nordisk and Eli Lilly. The company has raised $290 million and acquired or licensed several drug candidates that target different gut hormones.
Skip to content